Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

Leukemia and Lymphoma

Volumn 49, Issue 1, 2008, Pages 102-112

  Kimby, Eva ^a   Jurlander, Jesper ^b   Geisler, Christian ^b   Hagberg, Hans ^c   Holte, Harald ^d   Lehtinen, Tuula ^e   Östenstad, Björn ^f   Hansen, Mads ^a   Österborg, Anders ^a   Lindén, Ola ^g   Sundström, Christer ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Rigshospitalet   (Denmark)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Follicular lymphoma; Indolent lymphoma; Interferon; Molecular remission; Randomized phase II trial; Rituximab

Indexed keywords

ALPHA2A INTERFERON; RITUXIMAB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BLOOD DISEASE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FEVER; FOLLOW UP; GASTROINTESTINAL DISEASE; HUMAN; LYMPHATIC SYSTEM DISEASE; LYMPHOMA; MALE; MINIMAL RESIDUAL DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN DISEASE; SKIN MANIFESTATION; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URTICARIA;

EID: 38549100096     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701704647     Document Type: Article

References (23)

1. Gallagher, C. J., Gregory, W. M., Jones, A. E., Stansfeld, A. G., Richards, M. A. and Dhaliwai, H. S. (1986) Follicular lymphoma: prognostic factors for response and survival. J Clin Oncol, 4, pp. 1470-1480.
2. Hiddemann, W., Buske, C., Dreyling, M., Weigert, O., Lenz, G. and Forstpointner, R. (2005) Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol, 23, pp. 6394-6399.
3. Cartron, G., Watier, H. and Golay, J. (2004) From the bench to the bedside: Ways to improve rituximab efficacy. Blood, 104, pp. 2635-2642.
4. Plosker, G. L. and Figgitt, D. P. (2003) Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 63, pp. 803-843.
5. Czuczman, M. S., Koryzna, A., Mohr, A., Stewart, C., Donohue, K., Blumenson, L. and Bernstein, Z. P. (2005) Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. J Clin Oncol, 23, pp. 694-704.
6. Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E. and Catalano, J. (2005) CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood, 105, pp. 1417-1423.
7. Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E. and Schmits, R. (2005) Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomised study of the German Low Grade Lymphoma Study Group (GLSG). Blood, 106, pp. 3725-3732.
8. Herold, M., Haas, A., Srock, S., Neser, S., Al-Ali, K. H. and Neubauer, A. (2007) Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: An East German Study Group Hematology and Oncology. J Clin Oncol, 25, pp. 1986-1992.
9. Salles, G., Foussard, C., Mounier, N., Morschhauser, F., Doyen, C. and Lamy, T. Rituximab added to αIFN-CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: First analysis of the GELA-GOELAMS FL-2000 randomised trial in 359 patients. Blood (Suppl.) 2004:160
10. Sacchi, S., Federico, M., Vitolo, U., Boccoinini, C., Vallisa, D. and Baldini, L. (2001) Clinical activity and safety of combination immunotherapy with IFN-α2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. Haematologica, 86, pp. 951-958.
11. Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D. and Chan, W. C. (2004) Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med, 351, pp. 2159-2169.
12. Davis, T. A., Maloney, D. G., Grillo-López, A. J., White, C. A. and Williams, M. E. (2000) Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-α2a. Clin Cancer Res, 6, pp. 2644-2652.
13. Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K. and Vardiman, J. (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol, 17, pp. 3835-3849.
14. Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I. and Connors, J. M. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol, 17, pp. 1244-1253.
15. Gribben, J. G., Freedman, A., Woo, S. D., Blake, K., Shu, R. S. and Freeman, G. (1991) All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood, 78, pp. 3275-3280.
16. Deane, M. and Norton, J. D. (1990) Detection of immunoglobulin gene rearrangement in B lymphoid malignancies by polymerase chain reaction gene amplification. Br J Haematol, 74, pp. 251-256.
17. Fais, F., Ghiotto, F., Hashimoto, S., Sellars, B., Valetto, A. and Allen, S. L. (1998) Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest, 102, pp. 1515-1525.
18. Rohatiner, A. Z., Gregory, W. M., Peterson, B., Borden, E., Solal-Celignv, P. and Hagenbeek, A. (2005) Meta-analysis to evaluate the role of interferon in follicular lymphoma. J Clin Oncol, 23, pp. 2215-2223.
19. Ghielmini, M., Schmitz, S. F., Cogliatti, S. B., Pichert, G., Hummerjohann, J. and WaItzer, U. (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood, 103, pp. 4416-4423.
20. Piro, L. D., White, C. A., Grillo-López, A. J., Janakiraman, N., Saven, A. and Beck, T. M. (1999) Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol, 10, pp. 655-661.
21. Colombat, P., Salles, G., Brousse, N., Eftekhari, P., Soubevran, P. and Delwail, V. (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation. Blood, 97, pp. 101-106.
22. McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S. and Williams, M. E. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol, 16, pp. 2825-2833.
23. Kimby, E. (2005) Tolerability and safety of rituximab (MabThera™). Cancer Treat Rev, 31, pp. 456-473.